To evaluate the incidence of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2/neu) status in newly diagnosed breast carcinoma patients in a tertiary care centre and to compare the pattern of expression with age.
